Our findings highlight the presence of EV-A71 with a high degree of genetic diversity in patients with AFP in West Africa. Future studies about the burden of disease, epidemiologic features, and evolution of EV-A71 in this region of Africa are needed to implement appropriate public health measures.

Acknowledgments
We are grateful to Romain Volle and Florence Colbère-Garapin for critical review of the manuscript and to Hiroyuki Shimizu for fruitful discussions.

This work was supported by the Pasteur Institute’s Transverse Research Programs PTR-276 and PTR-484.

References
7. Zhang B, Wu X, Huang K, Li L, Zheng L, Wan C, et al. The safety of blood product use is continuously improving, but blood transfusion remains a challenge in Africa, given the high prevalence of bloodborne pathogens (1). In Africa, the main serologic tests done to reduce blood transfusion risks are for HIV and hepatitis B and C viruses. However, unknown or emerging pathogens among the population of blood donors, such as hepatitis E virus (HEV), may also jeopardize transfusion safety.

HEV is emerging as a potential threat to blood safety. High rates of HEV IgG prevalence among blood donors have been found in studies in the United States (7.7%), England (13.5%), France (16.6%), and Spain (19.6%) (2,3). A study in Iran showed a prevalence of 14.3% (4), and a study in China showed rates of up to 22.7% (5). Cases of HEV transmission by transfusion or transplantation have been reported, and recent studies in France and England showed risk for HEV in donorized blood ranging from 1/2,218 to 1/2,848 donations (5,6).

In Burkina Faso, the prevalence of HEV IgG has been reported as 11.6% among pregnant women during 2012. Prevalence is >70% among butchers, who form a population exposed to pigs, which are a reservoir for HEV (7,8). To determine whether HEV continues to circulate among human populations outside known at-risk populations, we investigated prevalence of HEV IgG and IgM in the blood donor population of Ouagadougou.

During June and July 2014, we recruited 1,497 first-time blood donors (398 women, 1,099 men) within the National Blood Transfusion Centre in Ouagadougou. Persons 17–65 years of age who weighed >50 kg were included (Figure, panel A). Candidate donors were excluded if they had previously received blood transfusions, had jaundice or clinical symptoms of hepatitis E, or had travel history to a country reporting hepatitis E. We included 1,066 donorized units in the analysis. We used a validated enzyme-linked immunosorbent assay (ELISA) to screen for HEV IgG and IgM antibodies (17).

Hepatitis E Virus Prevalence among Blood Donors, Ouagadougou, Burkina Faso
Kuan A. Traoré, Jean Bienvenue Ouoba, Hortense Rouamba, Yacouba K. Nébié, Honorine Dahourou, Frédéric Rossetto, Alfred S. Traoré, Nicolas Barro, Pierre Roques

Author affiliations: Centre de Recherche en Sciences Biologique Alimentaire Nutritionnelles, Université Ouaga 1–Pr. Joseph Ki-Zerbo, Ouagadougou, Burkina Faso (K.A. Traoré, J.B. Ouoba, A.S. Traoré, N. Barro); Commissariat à l’Energie Atomique, Service d’Immuno-Virologie, Fontenay-aux-Roses, France (K.A. Traoré, F. Rossetto, P. Roques); INSERM, U1184, Fontenay-aux-Roses (K.A. Traoré, F. Rossetto, P. Roques); Université Paris-Sud XI, Orsay, France (K.A. Traoré, F. Rossetto, P. Roques); Centre Médical de Samandin, Ouagadougou (H. Rouamba); Centre National de Transfusion Sanguine, Ouagadougou (Y.K. Nébié, H. Dahourou)

DOI: http://dx.doi.org/10.3201/eid2204.151728

To the Editor: The safety of blood product use is continually improving, but blood transfusion remains a challenge in Africa, given the high prevalence of bloodborne pathogens (1). In Africa, the main serologic tests done to reduce blood transfusion risks are for HIV and hepatitis B and C viruses. However, unknown or emerging pathogens among the population of blood donors, such as hepatitis E virus (HEV), may also jeopardize transfusion safety.

HEV is emerging as a potential threat to blood safety. High rates of HEV IgG prevalence among blood donors have been found in studies in the United States (7.7%), England (13.5%), France (16.6%), and Spain (19.6%) (2,3). A study in Iran showed a prevalence of 14.3% (4), and a study in China showed rates of up to 22.7% (5). Cases of HEV transmission by transfusion or transplantation have been reported, and recent studies in France and England showed risk for HEV in donorized blood ranging from 1/2,218 to 1/2,848 donations (5,6).

In Burkina Faso, the prevalence of HEV IgG has been reported as 11.6% among pregnant women during 2012. Prevalence is >70% among butchers, who form a population exposed to pigs, which are a reservoir for HEV (7,8). To determine whether HEV continues to circulate among human populations outside known at-risk populations, we investigated prevalence of HEV IgG and IgM in the blood donor population of Ouagadougou.

During June and July 2014, we recruited 1,497 first-time blood donors (398 women, 1,099 men) within the National Blood Transfusion Centre in Ouagadougou. Persons 17–65 years of age who weighed >50 kg were included (Figure, panel A). Candidate donors were excluded if they had previously received blood transfusions, had jaundice or clinical symptoms of hepatitis E, or had travel history to a country reporting hepatitis E. We included 1,066 donorized units in the analysis. We used a validated enzyme-linked immunosorbent assay (ELISA) to screen for HEV IgG and IgM antibodies (17).
signs of hepatitis, were pregnant, or had sexual contact with multiple partners. Demographic data collection was limited to age and sex, and residual serum specimens were anonymized as approved by the Ethics Committee of the National Blood Transfusion Centre. We used Dia.Pro IgG ELISA (Diagnostic Bioprobe Srl, Sesto San Giovanni, Italy) to detect HEV IgG; this assay uses HEV-specific synthetic antigens derived from open reading frame (ORF) 2 and ORF3 of all 4 HEV subtypes. We used Wantai ELISA (Wantai Biologic Pharmacy Enterprise Co., Ltd., Beijing, China) to test 92 randomly selected samples for HEV IgG, which showed concordant results (data not shown) (8). We also used the Wantai ELISA for the detection of HEV IgM; this test has a sensitivity of 97.1% (95% CI 94.6%–98.5%) and a specificity ranging from 95.3% in serum samples from patients with acute hepatitis A to 100% in healthy donors (http://www.ystwt.cn/IFU/HEV/HEV-IgM_CE.pdf). The HEV IgM positive samples were tested twice for accuracy. All tests were performed according to the manufacturers’ instructions; positive and negative controls were used in each plate.

The prevalence of HEV IgG was 39.0% (95% CI 36.5%–41.5%) by using Dia.Pro ELISA (Figure, panel B). This prevalence was twice that found in 2012 (8), but such wide variations were commonly found in Africa (9). In France, prevalence ranged widely, from 10% in the north to 52% in the south (6). HEV IgG prevalence increased significantly with age (p<0.001 by χ² test for trend) in both male and female donors, but age variation explained only partially the differences in the study population and those from a previous study (8). As described in France and other high-income countries (4,6), Traoré et al. found HEV genotype 3 in swine in Burkina Faso (10); thus, poor sanitation that disperses this oral–fecal transmitted virus might result in a high prevalence of HEV antibodies among the general population without causing epidemic illness that is more often associated to genotype 1.

Using the Wantai test, we found HEV IgM, a marker of recent infection, in samples from 2 women and 11 men in the blood donor population (1.9%, 95% CI 1.2–2.6% [Figure, panel C]). Samples from 7 men were positive for HEV IgG.

The HEV exposure prevalence we observed is similar to most of the published data from countries reporting endemic HEV and silent infection (6,7). IgM seroprevalence of 1.9% is indicative of low ongoing infection cycles, although no reference test is available (2). Our study was limited by the absence of HEV RNA screening to assess the presence of HEV particles and genotype in donated blood. However, HEV circulation is supported by 1) IgM signs of recent infection; 2) the commonality of silent infections with HEV, specifically genotype 3; and 3) another study that showed a clear, although rare, positive relationship between the number of IgM-positive samples and the number of HEV RNA-positive samples (4).
The risk for HEV infection through transfusions of donated blood emerged in West Africa in a similar way as described in European countries. Further assessment of the transfusion risk associated with HEV-positive donors will require an evaluation of HEV RNA in prospective donors and posttransfusion surveillance of occurrence of hepatitis.

Acknowledgments
We thank the nurses and staff of the National Blood Transfusion Center, Ouagadougou.

K.A.T. received funding from the 3rd-cycle university scholarship program of the Embassy of France in Burkina Faso (http://www.burkina.campusfrance.org) and a University Paris-Sud XI co-tutelle fellowship.

References

Address for correspondence: Pierre Roques, CEA, Division of Immuno-Virologie, Institute of Emerging Diseases and Innovative Therapies, INSERM, U1184, Fontenay-aux-Roses, France; email: pierre.roques@cea.fr

Porcine Deltacoronavirus, Thailand, 2015

Taveesak Janetanakit, Mongkol Lumpyai, Napawan Bunpapong, Supanat Boonyapisitsopa, Supassama Chaiyawong, Nutthawan Nonthabenjawan, Sawang Kesdaengsakonwut, Alongkorn Amonsin

Author affiliation: Chulalongkorn University, Bangkok, Thailand

DOI: http://dx.doi.org/10.3201/eid2204.151852

To the Editor: Porcine deltacoronavirus (PDCoV) was first reported in Hong Kong in 2012 and included the HKU15-44 and HKU15-155 strains (1). In early 2014, PDCoV was reported in pigs with diarrhea on swine farms in Ohio, USA (2), and later in other states (2–5). In April 2014, PDCoV strain KNU14-04 was reported in pigs in South Korea (6). A retrospective study in 2012 reported PDCoV strain S27 in Sichuan, China (7). Recently PDCoV strain CNJXN12 has been reported in pigs with diarrhea in Jiangxi, China (8).

There are currently 28 complete PDCoV genomes from China, South Korea, and the United States available in GenBank. We report emergence of PDCoV infections on a commercial swine farm in Thailand.

In June 2015, we investigated reports of acute diarrhea in piglets, gilts, and sows on a swine farm. An outbreak occurred on a commercial swine farm (3,000 sows) located in the eastern province of Thailand. Clinical signs, including acute watery diarrhea, loss of appetite, and agalactia, were observed in gilts and sows in the breeding and gestation houses. Subsequently, piglets in farrowing houses had clinical signs (depression, fever, watery diarrhea, and severe dehydration). Although clinical signs were detected less frequently in fattening pigs in growth-finishing houses, PDCoVs were later detected from blood samples of fattening pigs.

The outbreak lasted 6 weeks (June 10–July 20, 2015). The mortality rate was 27.63% (829/3,000) in sows and 64.27% (2,892/4,500) in piglets but was lower than that usually observed for porcine epidemic diarrhea virus (PEDV) infection. A total of 865 (19.22%) piglets died and were culled during 10 production weeks. Postmortem examination of dead piglets showed emaciated animals and yellow pasty feces. Intestines and colons showed thin walls with a watery content and curdled milk. Histopathologic examination showed shortened and fused villi in the jejunum and ileum. An attenuated and vacuolated cytoplasm in enterocytes was also observed (online Technical Appendix Figure 1, http://wwwnc.cdc.gov/EID/article/22/4/15-1852-Techapp1.pdf) (9,10).